Understanding the Potential Headwinds for Stryker Stock.

This evening we watched Stryker drop -2.1% to a price of $341.35 per share. The Large-Cap Medical Instruments & Supplies company is now trading -9.94% below its average target price of $379.01. Analysts have set target prices ranging from $345.0 to $406.0 per share for Stryker, and have given the stock an average rating of buy.

Stryker's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 1.1%. The stock's short ratio is 2.57. The company's insiders own 5.38% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.

Another number to watch is the company's rate of institutional share ownership, which now stands at 78.6%. In conclusion, we believe there is positive market sentiment regarding Stryker.

Institutions Invested in Stryker

Date Reported Holder Percentage Shares Value
2024-03-31 Vanguard Group Inc 8% 31,459,393 $10,738,663,992
2024-03-31 Blackrock Inc. 7% 26,244,709 $8,958,631,577
2024-03-31 Greenleaf Trust 5% 18,596,387 $6,347,876,815
2024-03-31 State Street Corporation 4% 14,352,621 $4,899,267,265
2024-03-31 Price (T.Rowe) Associates Inc 3% 11,879,897 $4,055,202,913
2024-03-31 Wellington Management Group, LLP 3% 10,836,402 $3,699,005,888
2024-03-31 Capital Research Global Investors 3% 9,982,717 $3,407,600,508
2024-03-31 JP Morgan Chase & Company 2% 8,651,403 $2,953,156,466
2024-03-31 Geode Capital Management, LLC 2% 6,581,012 $2,246,428,486
2024-03-31 FMR, LLC 2% 6,046,379 $2,063,931,508
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.